Tute Genomics has appointed Andrew Olson as vice president of sales.
"Tute Genomics is uniquely positioned to lead the revolution in genome-guided precision medicine," said Olson. "With the most comprehensive annotation database, now incorporating over 200 sources, Tute provides a high level of confidence to users that an important disease-causing DNA sequence variant will not be missed. A robust API, elegant user interface, and competitive pricing make Tute an attractive platform for rapid analysis of next generation sequencing data."
Olson has a strong track record of helping organizations successfully realize the potential of emerging biotechnologies. From 2007 to 2010, he was vice president of sales and marketing at Signature Genomics, an early leader in clinical genomics services. During his tenure, Olson was instrumental in bringing microarray technology to clinical cytogenetics, among other noteworthy achievements.
In addition to recruiting a high-performing sales and marketing team, Olson helped Signature Genomics capitalize on numerous commercial opportunities, growing the business at a heady pace. In recognition of this growth, Inc. 5000 included Signature Genomics on its list of Fastest Growing Companies in 2008 and 2009. The company was acquired by PerkinElmer in 2010.
Most recently, Olson held the vice president of sales position at Great Basin Corporation, a Utah-based healthcare technology firm. His most important accomplishments there included establishing international distribution agreements in New Zealand and member states of the European Union. Likewise, he was a major contributor to the launch of an FDA-cleared product in November 2012.
"Andy's experience in commercializing emerging technologies, specifically those that aid in the discovery and diagnosis of genetic diseases, makes him a great addition to our team," said Reid Robison, MD MBA, CEO of Tute Genomics.
Olson's academic credentials showcase a firm grounding in both science and business. He earned a Bachelor of Science in molecular biology from Brigham Young University and a Master of Business Administration from the University of Houston.
Following on the heels of its recently announced addition in Illumina's BaseSpace and Series A1 funding raise, Tute Genomics' selection of Olson as its new sales VP indicates the company is primed for growth. The field of clinical genomics will only become more dynamic as technology pushes the frontiers of knowledge in new directions; thus, having a leader on board who has not only managed change but driven it will be a profound advantage moving forward.
Tute Genomics has developed a genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Tute has created an unprecedented knowledge-base of genetic variants consisting of public and private data sources and scoring algorithms.